{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:53:11Z","timestamp":1761922391744,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000996","name":"Department of Foreign Affairs and Trade, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1124130","APP1130301"],"award-info":[{"award-number":["APP1124130","APP1130301"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ijpddr.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T23:38:46Z","timestamp":1653003526000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children"],"prefix":"10.1016","volume":"19","author":[{"given":"Sri Riyati","family":"Sugiarto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George M.","family":"Bwire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9792-7838","authenticated-orcid":false,"given":"Brioni R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Page-Sharp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-5351","authenticated-orcid":false,"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3850-1778","authenticated-orcid":false,"given":"Kevin T.","family":"Batty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omary M.S.","family":"Minzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Billy","family":"Ngasala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0749-7411","authenticated-orcid":false,"given":"Timothy M.E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-6250","authenticated-orcid":false,"given":"Julie","family":"Makani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-6784","authenticated-orcid":false,"given":"Sam","family":"Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2022.05.002_bib1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(08)61492-0","article-title":"Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial","volume":"372","author":"Abdulla","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/1475-2875-13-369","article-title":"A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria","volume":"13","author":"Adjei","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.curtheres.2019.01.005","article-title":"Population pharmacokinetic estimates suggest elevated clearance and distribution volume of desethylamodiaquine in pediatric patients with sickle cell disease treated with artesunate-amodiaquine","volume":"90","author":"Adjei","year":"2019","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/004947550103100109","article-title":"Associated morbidities in children with sickle-cell anaemia presenting with severe anaemia in a malarious area","volume":"31","author":"Ambe","year":"2001","journal-title":"Trop. Doct."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26735","article-title":"High birth prevalence of sickle cell disease in Northwestern Tanzania","volume":"65","author":"Ambrose","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2471\/BLT.20.253583","article-title":"Surveillance for sickle cell disease, United Republic of Tanzania","volume":"98","author":"Ambrose","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic basis of using body size and maturation to predict clearance in humans","volume":"24","author":"Anderson","year":"2009","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-3156.2006.01785.x","article-title":"Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria","volume":"12","author":"Ashley","year":"2007","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s002280000155","article-title":"Cardiac effects of co-artemether (artemether\/lumefantrine) and mefloquine given alone or in combination to healthy volunteers","volume":"56","author":"Bindschedler","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4155\/bio.12.294","article-title":"Heat stabilization of blood spot samples for determination of metabolically unstable drug compounds","volume":"5","author":"Blessborn","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib11","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/jac\/dkr596","article-title":"Lopinavir\/ritonavir significantly influences pharmacokinetic exposure of artemether\/lumefantrine in HIV-infected Ugandan adults","volume":"67","author":"Byakika-Kibwika","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jpain.2010.10.012","article-title":"Increased clearance of morphine in sickle cell disease: implications for pain management","volume":"12","author":"Darbari","year":"2011","journal-title":"J. Pain"},{"issue":"Suppl. 1","key":"10.1016\/j.ijpddr.2022.05.002_bib13","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2875-8-S1-S4","article-title":"Understanding the pharmacokinetics of coartem","volume":"8","author":"Djimde","year":"2009","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib14","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.4081\/hr.2011.e24","article-title":"Sickle cell protection from malaria","volume":"3","author":"Eridani","year":"2011","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","article-title":"Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria","volume":"44","author":"Ezzet","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/QAI.0b013e3181acb4ff","article-title":"Lopinavir\/Ritonavir affects pharmacokinetic exposure of artemether\/lumefantrine in HIV-uninfected healthy volunteers","volume":"51","author":"German","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3476(98)70396-8","article-title":"Hepatic function as assessed by lidocaine metabolism in sickle cell disease","volume":"132","author":"Gremse","year":"1998","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4269\/ajtmh.2008.78.241","article-title":"Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study","volume":"78","author":"Hatz","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib19","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1128\/AAC.00252-10","article-title":"Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania","volume":"54","author":"Hietala","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib20","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/pbc.26207","article-title":"Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease","volume":"63","author":"Horst","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2471\/BLT.10.080010","article-title":"Blood sample volumes in child health research: review of safe limits","volume":"89","author":"Howie","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib22","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4155\/bio.13.91","article-title":"Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method","volume":"5","author":"Huang","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib23","article-title":"Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients","volume":"13","author":"Huang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/QAI.0000000000002237","article-title":"Efavirenz-based antiretroviral therapy reduces artemether-lumefantrine exposure for malaria treatment in HIV-infected pregnant women","volume":"83","author":"Hughes","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib25","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1128\/AAC.42.9.2332","article-title":"Effects of alpha-thalassemia on pharmacokinetics of the antimalarial agent artesunate","volume":"42","author":"Ittarat","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1172\/JCI116994","article-title":"Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes","volume":"93","author":"Kamchonwongpaisan","year":"1994","journal-title":"J. Clin. Invest."},{"year":"2022","series-title":"Splenic Sequestration Crisis, StatPearls, Treasure Island (FL)","author":"Kane","key":"10.1016\/j.ijpddr.2022.05.002_bib27"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib28","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1128\/AAC.48.8.2966-2972.2004","article-title":"Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria","volume":"48","author":"Karunajeewa","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib29","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1038\/psp.2013.59","article-title":"Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda","volume":"2","author":"Kloprogge","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib30","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1128\/AAC.00267-15","article-title":"Lumefantrine and desbutyl-lumefantrine population pharmacokinetic-pharmacodynamic relationships in pregnant women with uncomplicated Plasmodium falciparum malaria on the Thailand-Myanmar border","volume":"59","author":"Kloprogge","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002579","article-title":"Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: a pharmacokinetic-pharmacodynamic meta-analysis","volume":"15","author":"Kloprogge","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1086\/599834","article-title":"Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya","volume":"49","author":"Komba","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12879-016-1345-1","article-title":"The interaction between artemether-lumefantrine and lopinavir\/ritonavir-based antiretroviral therapy in HIV-1 infected patients","volume":"16","author":"Kredo","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00044011-199918060-00006","article-title":"Clinical pharmacokinetics of artemether and lumefantrine (Riamet (R))","volume":"18","author":"Lefevre","year":"1999","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/009127002237995","article-title":"Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects","volume":"42","author":"Lefevre","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00518-18","article-title":"Population pharmacokinetics of artemether, dihydroartemisinin, and lumefantrine in Rwandese pregnant women treated for uncomplicated Plasmodium falciparum malaria","volume":"62","author":"Lohy Das","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12936-015-0695-2","article-title":"The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment","volume":"14","author":"Maganda","year":"2015","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2009-07-233528","article-title":"Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization","volume":"115","author":"Makani","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00637-17","article-title":"Population pharmacokinetics of cefotaxime and dosage recommendations in children with sickle cell disease","volume":"62","author":"Maksoud","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib40","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2010-01-265249","article-title":"High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya","volume":"116","author":"McAuley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib41","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00228-006-0199-7","article-title":"The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria","volume":"62","author":"McGready","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12936-017-1819-7","article-title":"The malaria testing and treatment landscape in mainland Tanzania","volume":"16","author":"Michael","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/AAC.00679-09","article-title":"Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda","volume":"54","author":"Mwesigwa","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib44","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4269\/ajtmh.14-0490","article-title":"Comparing the impact of artemisinin-based combination therapies on malaria transmission in sub-Saharan Africa","volume":"92","author":"Ndeffo Mbah","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12936-015-0918-6","article-title":"Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study","volume":"14","author":"Ndounga","year":"2015","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2017.05.043","article-title":"Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: a case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin","volume":"106","author":"Olafuyi","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V53.3.358.358","article-title":"Developmental aspects of splenic function in sickle cell diseases","volume":"53","author":"Pearson","year":"1979","journal-title":"Blood"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib48","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1128\/AAC.05136-11","article-title":"Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria","volume":"55","author":"Salman","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib49","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/17425255.2017.1391212","article-title":"Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations","volume":"13","author":"Sugiarto","year":"2017","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib50","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/cid\/cix785","article-title":"Artemisinin therapy for malaria in hemoglobinopathies: a systematic review","volume":"66","author":"Sugiarto","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib51","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/bcp.15001","article-title":"The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria","volume":"88","author":"Sugiarto","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib52","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.4155\/bio.13.180","article-title":"Dried blood spots in bioanalysis of antimalarials: relevance and challenges in quantitative assessment of antimalarial drugs","volume":"5","author":"Taneja","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib53","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1128\/AAC.00195-09","article-title":"Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria","volume":"53","author":"Tarning","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib54","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1473-3099(12)70055-5","article-title":"Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis","volume":"12","author":"Taylor","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib55","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/infdis\/jiw338","article-title":"Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria","volume":"214","author":"Tchaparian","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2022.05.002_bib56","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1128\/AAC.01312-10","article-title":"Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome","volume":"55","author":"Wong","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"year":"2021","series-title":"WHO Guidelines for Malaria","key":"10.1016\/j.ijpddr.2022.05.002_bib57"},{"key":"10.1016\/j.ijpddr.2022.05.002_bib58","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamapediatrics.2018.3227","article-title":"Duration of pediatric clinical trials submitted to the US Food and Drug Administration","volume":"173","author":"Zimmerman","year":"2019","journal-title":"JAMA Pediatr."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320722000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320722000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:51:11Z","timestamp":1761922271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320722000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":58,"alternative-id":["S2211320722000082"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2022.05.002","relation":{},"ISSN":["2211-3207"],"issn-type":[{"type":"print","value":"2211-3207"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}